A review of the therapeutic role of bosutinib in chronic myeloid leukemia
The development of the BCR::ABL1 tyrosine kinase inhibitors (TKIs) has transformed Philadelphia chromosome (Ph) –positive chronic myeloid leukemia (CML) from a fatal disease to an often-indolent illness that, when managed effectively, can restore a life expectancy close to that of the normal population. Bosutinib is a second-generation TKI approved for adults with Ph-positive CML in chronic phase, accelerat ed phase, or blast phase that is resistant or intolerant to prior therapy, and for newly diagnosed Ph-positive chronic phase CML.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: H.M. Kantarjian, E.J. Jabbour, J.H. Lipton, F. Castagnetti, T.H. Br ümmendorf Tags: Review Article Source Type: research
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Hematology | Leukemia | Lymphoma | Myeloma